Volume 14, Issue 5 (July 2020)
Qom Univ Med Sci J 2020, 14(5): 22-29 |
Back to browse issues page
1- Islamic Azad University, Science and Research Branch, Faculty of Basic Sciences, Department of Genetics, Tehran, Iran.
2- National Institute of Genetic Engineering and Biotechnology, Institute of Medical Biotechnology, Department of Molecular Medicine, Tehran, Iran. ,shahlamg@yahoo.com
2- National Institute of Genetic Engineering and Biotechnology, Institute of Medical Biotechnology, Department of Molecular Medicine, Tehran, Iran. ,
Abstract: (2770 Views)
Background and Objectives: Glioblastoma is one of the most malignant and common brain tumors, accounting for about half of all gliomas. Glioblastoma is a central nervous system tumor that originates from the glial tissue of the brain. The present study aimed to investigate changes in the expression of long non-coding RNA HOXA11-AS as a possible biomarker in glioma.
Methods: For the purposes of the present study, first, the medical records of the patients in Imam Hossein Hospital in Tehran, Iran were reviewed. The ethical considerations were respected as well; accordingly, written informed consent was obtained from the patients and the code of ethics was achieved as well. Finally, the paraffin blocks, including the biopsy of brain tumor tissue of the patients who referred to Imam Hossein Hospital during 2015-17 were collected and their degrees were confirmed by the pathologist. In total, 50 samples of grades 1 and 2 as well as 50 samples of grades 3 and 4 were examined in this research project. The RNA extraction and cDNA synthesis were performed for all the tissue samples donated by the patients. Subsequently, a specific primer and probe were designed and the expression of the HOXA11-AS gene was investigated using real-time polymerase chain reaction technique. The mean age of the subjects was 43.70±16.416 years. The collected data were analyzed in SPSS software (version 20) using descriptive and analytical statistics. Moreover, the expression levels of this gene in lower- and higher-grade tumor tissues were compared using the unpaired samples t-test.
Results: Based on the results, the tumor samples with grade three and four underwent a 2.76 fold increase in expression (fold change), compared to tumor samples with grade one and two. This difference was statistically significant.
Methods: For the purposes of the present study, first, the medical records of the patients in Imam Hossein Hospital in Tehran, Iran were reviewed. The ethical considerations were respected as well; accordingly, written informed consent was obtained from the patients and the code of ethics was achieved as well. Finally, the paraffin blocks, including the biopsy of brain tumor tissue of the patients who referred to Imam Hossein Hospital during 2015-17 were collected and their degrees were confirmed by the pathologist. In total, 50 samples of grades 1 and 2 as well as 50 samples of grades 3 and 4 were examined in this research project. The RNA extraction and cDNA synthesis were performed for all the tissue samples donated by the patients. Subsequently, a specific primer and probe were designed and the expression of the HOXA11-AS gene was investigated using real-time polymerase chain reaction technique. The mean age of the subjects was 43.70±16.416 years. The collected data were analyzed in SPSS software (version 20) using descriptive and analytical statistics. Moreover, the expression levels of this gene in lower- and higher-grade tumor tissues were compared using the unpaired samples t-test.
Results: Based on the results, the tumor samples with grade three and four underwent a 2.76 fold increase in expression (fold change), compared to tumor samples with grade one and two. This difference was statistically significant.
Conclusion: Based on the findings, it can be concluded that the expression of the HOXA11-AS gene has a significant positive relationship with the degree of disease (P=0.0002).
Type of Study: Original Article |
Subject:
علوم پایه
Received: 2020/05/14 | Accepted: 2020/07/22 | Published: 2020/07/31
Received: 2020/05/14 | Accepted: 2020/07/22 | Published: 2020/07/31
References
1. 1. Malmer B, Henriksson R, Grönberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first‐degree relatives of brain tumour patients. Int J Cancer 2003;106(2):260-3. PMID: 12800203 [DOI:10.1002/ijc.11213]
2. Holland EC. Glioblastoma multiforme: the terminator. Proc Natil Acad Sci 2000;97(12):6242-4. PMID: 10841526 [DOI:10.1073/pnas.97.12.6242]
3. Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 2017;8:99-113. PMID: 28989289 [DOI:10.2147/AHMT.S53391]
4. Baskaran S. New molecular approaches to glioblastoma therapy. [Doctoral Dissertation]. Uppsala: Acta Universitatis Upsaliensis; 2017. Link
5. Li Q, Jia H, Li H, Dong C, Wang Y, Zou Z. LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis. Tumour Biol 2016;37(11):14537-52. PMID: 27604987 [DOI:10.1007/s13277-016-5299-0]
6. Chen G, Cao Y, Zhang L, Ma H, Shen C, Zhao J. Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas. Oncotarget 2017;8(40):67744-53. PMID: 28978068 [DOI:10.18632/oncotarget.18832]
7. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012;488(7409):111-5. PMID: 22859208 [DOI:10.1038/nature11362]
8. Seydoux G, Braun RE. Pathway to totipotency: lessons from germ cells. Cell 2006;127(5):891-904. PMID: 17129777 [DOI:10.1016/j.cell.2006.11.016]
9. Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nat Rev Clini Oncol 2019;16(8):509-20. PMID: 30733593 [DOI:10.1038/s41571-019-0177-5]
10. Rahmati S, Emadi Baigi M. Glioblastoma multi form. First National Conference on Biological Sciences, Islamic Azad University, Falavarjan, Iran; 2012. Link
11. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood) 2018;243(3):213-21. PMID: 29405771 [DOI:10.1177/1535370217750088]
12. Noori-Daloii MR, Eshaghkhani Y. lncRNAs roles in cancer occurrence. Med Sci J Islam Azad Univ Tehran Med Branch 2015;25(3):163-82. Link
13. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006;11(2):152-64. PMID: 16476836 [DOI:10.1634/theoncologist.11-2-152]
14. Wang Q, Zhang J, Liu Y, Zhang W, Zhou J, Duan R, et al. A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett 2016;373(2):251-9. PMID: 26828136 [DOI:10.1016/j.canlet.2016.01.039]
15. Cao K, Fang Y, Wang H, Jiang Z, Guo L, Hu Y. The lncRNA HOXA11-AS regulates Rab3D expression by sponging miR-125a-5p promoting metastasis of osteosarcoma. Cancer Manag Res 2019;11:4505-18. PMID: 31191012 [DOI:10.2147/CMAR.S196025]
16. Li B, Wang W, Miao S, Li G, Lv Y, Xiang C, et al. HOXA11-AS promotes the progression of oral squamous cell carcinoma by targeting the miR-518a-3p/PDK1 axis. Cancer Cell Int 2019;19(1):140. PMID: 31139017 [DOI:10.1186/s12935-019-0838-6]
17. Xu C, He T, Li Z, Liu H, Ding B. Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells. Biomed Pharmacother 2017;95:1504-13. PMID: 28946213 [DOI:10.1016/j.biopha.2017.08.097]
18. Mu S, Ai L, Fan F, Sun C, Hu Y. Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis. Cancer Cell Int 2018;18:1. PMID: 29308050 [DOI:10.1186/s12935-017-0498-3]
19. Zhang Z, Zhou J, Zhang J, Duan R, Pu P, Han L. Downregulation of lncRNA-HOXA11-AS modulates proliferation and stemness in Glioma cells. Chin Neurosurg J 2017;3(1):1-7. Link [DOI:10.1186/s41016-017-0091-6]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |